173 related articles for article (PubMed ID: 23757746)
1. European Medicines Agency must take account of cardiovascular harm associated with degludec insulin.
Schmidt TA; Rosen CJ; Yudkin JS
BMJ; 2013 Jun; 346():f3731. PubMed ID: 23757746
[No Abstract] [Full Text] [Related]
2. Assessing the cardiovascular safety of diabetes therapies.
Goldfine AB
N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
[No Abstract] [Full Text] [Related]
3. FDA raises concerns about ultra-long acting insulins given green light in Europe and Japan.
Torjesen I
BMJ; 2012 Oct; 345():e7323. PubMed ID: 23112064
[No Abstract] [Full Text] [Related]
4. The Avandia debate: an unhappy conclusion.
Bloomgarden Z; Handelsman Y
J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
[No Abstract] [Full Text] [Related]
5. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
Hiatt WR; Kaul S; Smith RJ
N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
[No Abstract] [Full Text] [Related]
6. Warning: dangers of insulin at 200 units per ml.
Prescrire Int; 2014 Apr; 23(148):111. PubMed ID: 24860907
[No Abstract] [Full Text] [Related]
7. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
Rosen CJ
N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
[No Abstract] [Full Text] [Related]
8. FDA committee urges tight restrictions on rosiglitazone.
Roehr B
BMJ; 2010 Jul; 341():c3862. PubMed ID: 20639290
[No Abstract] [Full Text] [Related]
9. [Clinical use of long-acting insulin analogs].
Birkeland KI
Tidsskr Nor Laegeforen; 2006 Apr; 126(8):1067-8. PubMed ID: 16619068
[No Abstract] [Full Text] [Related]
10. FDA puts restrictions on use of controversial diabetes drug.
Mayo Clin Womens Healthsource; 2011 Feb; 15(2):3. PubMed ID: 21200371
[No Abstract] [Full Text] [Related]
11. Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?
Freemantle N
BMJ; 2010 Sep; 341():c4812. PubMed ID: 20819888
[No Abstract] [Full Text] [Related]
12. Rosiglitazone: what went wrong?
Cohen D
BMJ; 2010 Sep; 341():c4848. PubMed ID: 20819889
[No Abstract] [Full Text] [Related]
13. Potential harms of type 2 diabetes drugs have been ignored, finds BMJ investigation.
Kmietowicz Z
BMJ; 2013 Jun; 346():f3782. PubMed ID: 23757752
[No Abstract] [Full Text] [Related]
14. Potential Issues With New Basal Insulin/GLP-1 Fixed Combinations.
Shastay A
Home Healthc Now; 2019; 37(2):120-121. PubMed ID: 30829792
[No Abstract] [Full Text] [Related]
15. Insulin degludec for diabetes mellitus.
Drug Ther Bull; 2013 Jul; 51(7):78-81. PubMed ID: 23842634
[TBL] [Abstract][Full Text] [Related]
16. Hypoglycemia rates with basal insulin analogs.
Little S; Shaw J; Home P
Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S53-64. PubMed ID: 21668338
[TBL] [Abstract][Full Text] [Related]
17. The record on rosiglitazone and the risk of myocardial infarction.
Psaty BM; Furberg CD
N Engl J Med; 2007 Jul; 357(1):67-9. PubMed ID: 17551162
[No Abstract] [Full Text] [Related]
18. [Early insulin therapy in type 2 diabetes?].
Birkeland KI
Tidsskr Nor Laegeforen; 2012 Oct; 132(19):2151-2. PubMed ID: 23076480
[No Abstract] [Full Text] [Related]
19. Cardiovascular safety of long-acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?
Chang CH; Chuang LM
J Diabetes Investig; 2018 Jul; 9(4):728-730. PubMed ID: 29140602
[No Abstract] [Full Text] [Related]
20. Top adviser at the European Medicines Agency quits suddenly.
Benkimoun P
BMJ; 2012 Apr; 344():e2641. PubMed ID: 22496308
[No Abstract] [Full Text] [Related]
[Next] [New Search]